MiniMed Group (MMED) SEC filings document the regulatory record of a Nasdaq-listed diabetes technology company focused on insulin delivery systems, CGMs, sensors, algorithms, and app-connected diabetes management. MiniMed's filings include annual reports, quarterly reports, proxy statements, and Form 8-K material event reports.
For MMED, the most relevant filings often relate to medical device operations and newly public company governance. Annual reports and 10-Q filings can describe business structure, risk factors, capital structure, financial results, clinical and regulatory matters, and disclosures tied to MiniMed's separation from Medtronic. Form 8-K filings have covered financial results, board appointments, executive compensation plans, officer departures, cybersecurity-related disclosures, and other material events.
Proxy statements are useful for reviewing director elections, auditor ratification, advisory compensation votes, and governance matters. Form 4 insider transaction filings can show reported purchases, sales, or equity awards by directors and officers when such filings are submitted. 10-K and 10-Q reports are especially important for understanding how MiniMed reports its diabetes technology business after becoming a public company.
AI-powered summaries can translate dense filing language into plain-English explanations, while real-time EDGAR updates can surface new MMED filings as they are released. These summaries are most useful when reviewing long annual reports, quarterly updates, proxy statements, and insider transaction disclosures.
MiniMed Group, Inc. executive Chad Spooner, who serves as EVP and Chief Financial Officer, filed an initial statement of beneficial ownership on Form 3. The filing does not list any buy, sell, or other insider transactions and shows no derivative positions or holdings entries.
MiniMed Group, Inc. director and Chief Executive Officer Dallara Que filed an initial ownership report on Form 3. This filing establishes Que’s status as an insider of the company but does not list any transactions or specific share holdings.
MiniMed Group, Inc. President Eso Christopher filed an initial ownership report on Form 3. This filing identifies him as an officer of the company but does not list any specific share holdings or transactions. It is a routine SEC disclosure required when someone becomes an insider.
MiniMed Group, Inc. director Brian Sandstrom filed an initial Form 3, which is a statement of beneficial ownership for company insiders. This filing lists him as a director of MiniMed Group but does not report any insider stock transactions.